The Journal of the Korean Rheumatism Association 2003; 10(1): 16-22
Published online March 30, 2003
© Korean College of Rheumatology
김윤아·이신석*·박미정*
서남대학교 의과대학 내과학교실, 전남대학교 의과대학 내과학교실*
Correspondence to : Shin-Seok Lee
Objective: To determine whether levels of soluble Fas (sFas) are elevated in patients with systemic lupus erythematosus (SLE) and correlated with clinical disease activity.
Methods: Serum samples were obtained from 62 SLE patients and 39 normal controls. We measured sFas levels using an enzyme-linked immunosorbent assay. Disease activity variables including Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were examined. Results: The mean age of the patients was 32.1 years (range 13∼60 years) and the mean disease duration was 3.0 years (range 0.2∼10.0 years); 1 patient was male (1.6%). The median serum sFas concentration was 610.0 pg/ml for SLE patients and 292.9 pg/ml in controls. The serum sFas concentration was significantly higher in SLE patients than in controls (p<0.001). The Receiver Operating Characteristics (ROC) curve showed that the area under the curve for sFas was 0.911. Using the cut-off value of 370.5 pg/ml, the sensitivity was 0.871 and the specificity was 0.846. However, we could not find any correlation between sFas levels and disease activity variables such as SLEDAI, complement, and anti-dsDNA antibodies. There was no significant difference in sFas levels between active (SLEDAI ≥8) and inactive (SLEDAI <8) SLE patients. Conclusion: These results suggest that sFas levels are elevated in SLE patients, but sFas does not reflect disease activity.
Keywords Systemic lupus erythematosus, Soluble Fas, Disease activity
The Journal of the Korean Rheumatism Association 2003; 10(1): 16-22
Published online March 30, 2003
Copyright © Korean College of Rheumatology.
김윤아·이신석*·박미정*
서남대학교 의과대학 내과학교실, 전남대학교 의과대학 내과학교실*
Yun-A Kim, M.D., Shin-Seok Lee, M.D.*, Mi-Jeong Park, M.D.*
Department of Internal Medicine, Seonam University College of Medicine, Gwangju Department of Internal Medicine*, Chonnam National University Medical School, Gwangju, Korea
Correspondence to:Shin-Seok Lee
Objective: To determine whether levels of soluble Fas (sFas) are elevated in patients with systemic lupus erythematosus (SLE) and correlated with clinical disease activity.
Methods: Serum samples were obtained from 62 SLE patients and 39 normal controls. We measured sFas levels using an enzyme-linked immunosorbent assay. Disease activity variables including Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were examined. Results: The mean age of the patients was 32.1 years (range 13∼60 years) and the mean disease duration was 3.0 years (range 0.2∼10.0 years); 1 patient was male (1.6%). The median serum sFas concentration was 610.0 pg/ml for SLE patients and 292.9 pg/ml in controls. The serum sFas concentration was significantly higher in SLE patients than in controls (p<0.001). The Receiver Operating Characteristics (ROC) curve showed that the area under the curve for sFas was 0.911. Using the cut-off value of 370.5 pg/ml, the sensitivity was 0.871 and the specificity was 0.846. However, we could not find any correlation between sFas levels and disease activity variables such as SLEDAI, complement, and anti-dsDNA antibodies. There was no significant difference in sFas levels between active (SLEDAI ≥8) and inactive (SLEDAI <8) SLE patients. Conclusion: These results suggest that sFas levels are elevated in SLE patients, but sFas does not reflect disease activity.
Keywords: Systemic lupus erythematosus, Soluble Fas, Disease activity
Bong-Woo Lee, M.D., Eui-Jong Kwon, M.D., Ji Hyeon Ju, M.D., Ph.D.
J Rheum Dis -0001; ():So-Young Bang, M.D., Ph.D., Seung Cheol Shim, M.D., Ph.D.
J Rheum Dis 2024; 31(4): 200-211Alhanouf Adnan Alsharif, M.B.B.S., Abdulaziz Marzouq Almutairi, M.D., Emtenan Badar Basahl, M.B.B.S., Abdulaziz Abdulllah Alshathri, M.D., Jameela Abdulaziz Kari, M.D., Mohammed Ahmad Shalaby, M.D., Mohammed Ahmad Nashawi, M.D.
J Rheum Dis 2025; 32(1): 57-62